Company Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital.
The company was founded in 2015 and is based in Wilmington, Delaware.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jonathan Javitt |
Contact Details
Address: 1201 Orange Street, Suite 600 Wilmington, Delaware 19801 United States | |
| Phone | (484) 254-6134 |
| Website | nrxpharma.com |
Stock Details
| Ticker Symbol | NRXP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001719406 |
| CUSIP Number | 089482103 |
| ISIN Number | US6294441000 |
| Employer ID | 82-2844431 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Patrick Duffy | Chief Business Officer and Co-Chief Executive Officer of Hope Therapeutics |
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman and Interim Chief Executive Officer |
| Richard Clavano Narido | Chief Financial Officer and Treasurer |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing and Technology Officer |
| Suzanne Messere | Investor Relations |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 8-K | Current Report |
| Sep 5, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 27, 2024 | PRE 14A | Other preliminary proxy statements |
| Aug 20, 2024 | 8-K | Current Report |